These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23777764)

  • 1. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.
    Williams LA; Garcia Gonzalez AG; Ault P; Mendoza TR; Sailors ML; Williams JL; Huang F; Nazha A; Kantarjian HM; Cleeland CS; Cortes JE
    Blood; 2013 Aug; 122(5):641-7. PubMed ID: 23777764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
    Mendoza TR; Wang XS; Lu C; Palos GR; Liao Z; Mobley GM; Kapoor S; Cleeland CS
    Oncologist; 2011; 16(2):217-27. PubMed ID: 21285393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
    Armstrong TS; Gning I; Mendoza TR; Vera-Bolanos E; Gilbert MR; Rhines LD; Weinberg JS; Sanchez-Williams G; Levin V; Burton AW; Cleeland C
    J Neurosurg Spine; 2010 Apr; 12(4):421-30. PubMed ID: 20367379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
    Wang XS; Shi Q; Williams LA; Cleeland CS; Garcia-Gonzalez A; Chen TY; Shahid DR; Ramirez PT; Iniesta MD; Siverand AM; Meyer LA
    Gynecol Oncol; 2019 Mar; 152(3):492-500. PubMed ID: 30876494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory.
    Gning I; Trask PC; Mendoza TR; Harle MT; Gutierrez KA; Kitaka SA; Sherman SI; Cleeland CS
    Oncology; 2009; 76(1):59-68. PubMed ID: 19052478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.
    Mendoza TR; Zhao F; Cleeland CS; Wagner LI; Patrick-Miller LJ; Fisch MJ
    Clin Breast Cancer; 2013 Oct; 13(5):325-34. PubMed ID: 23816985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI).
    Wang XS; Williams LA; Eng C; Mendoza TR; Shah NA; Kirkendoll KJ; Shah PK; Trask PC; Palos GR; Cleeland CS
    Cancer; 2010 Apr; 116(8):2053-63. PubMed ID: 20166216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep.
    Wang XS; Shi Q; Williams LA; Lillemoe HA; Chen TY; Gottumukkala V; Garcia-Gonzalez A; Malveaux D; Kamal M; Cleeland CS; Aloia TA
    Eur J Oncol Nurs; 2021 Jun; 52():101959. PubMed ID: 33964632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and Application of the Chinese Version of the M. D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C).
    Chen RW; Yang SL; Xu ZY; Peng M; Chen MN; Wang QS; Chang J; Hu JL
    J Pain Symptom Manage; 2019 Apr; 57(4):820-827. PubMed ID: 30684634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID).
    Williams LA; Whisenant MS; Mendoza TR; Peek AE; Malveaux D; Griffin DK; Ponce DA; Granwehr BP; Sheshadri A; Hutcheson KA; Ali SM; Peterson SK; Heymach JV; Cleeland CS; Subbiah IM
    J Patient Rep Outcomes; 2023 May; 7(1):48. PubMed ID: 37237077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.
    Tanaka S; Sato I; Takahashi M; Armstrong TS; Cleeland CS; Mendoza TR; Mukasa A; Takayanagi S; Narita Y; Kamibeppu K; Saito N
    Jpn J Clin Oncol; 2020 Jul; 50(7):787-793. PubMed ID: 32280995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.
    Sailors MH; Bodurka DC; Gning I; Ramondetta LM; Williams LA; Mendoza TR; Agarwal S; Sun CC; Cleeland CS
    Gynecol Oncol; 2013 Aug; 130(2):323-8. PubMed ID: 23685012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer.
    Williams LA; Agarwal S; Bodurka DC; Saleeba AK; Sun CC; Cleeland CS
    J Pain Symptom Manage; 2013 Dec; 46(6):837-45. PubMed ID: 23615044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and Application of the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM).
    Li Z; Shi Q; Liu M; Jia L; He B; Yang Y; Liu J; Lin H; Lin HK; Li P; Wang XS
    J Natl Cancer Inst Monogr; 2017 Nov; 2017(52):. PubMed ID: 29140491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.
    Rosenthal DI; Mendoza TR; Chambers MS; Asper JA; Gning I; Kies MS; Weber RS; Lewin JS; Garden AS; Ang KK; S Wang X; Cleeland CS
    Head Neck; 2007 Oct; 29(10):923-31. PubMed ID: 17358040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the MD Anderson Symptom Inventory-Head-and-Neck-Filipino (MDASI-HN-F): clinical utility of symptom screening among patients with head-and-neck cancer.
    Bacorro WR; Sy Ortin TT; Suarez CG; Mendoza TR; Que JC
    BMJ Support Palliat Care; 2017 Jun; 7(2):140-149. PubMed ID: 25941198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
    J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-sectional Study on the Symptom Burden of Patients With Spinal Tumor: Validation of the Chinese Version of the M.D. Anderson Symptom Inventory-Spine Tumor Module.
    Xu N; Li Z; Wei F; Liu X; Jiang L; Meng N; Jiang P; Yu M; Wu F; Dang L; Zhou H; Li Y; Liu Z
    J Pain Symptom Manage; 2017 Mar; 53(3):605-613. PubMed ID: 28042067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting.
    Kamal M; Navai N; Bree KK; Williams LA; Cleeland CS; Shen SE; Wang XS
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
    Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.